After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $58.54 and fluctuated between $59.10 as its day high and $58.10 as its day low. The current market capitalization of Incyte Corp. is $13.14B. A total of 1.22 million shares were traded on the day, compared to an average of 1.75M shares.
In the most recent transaction, Stein Steven H sold 7,365 shares of INCY for 65.51 per share on Jan 03 ’24. After the transaction, the EVP & Chief Medical Officer now owns 90,218 company shares. In a previous transaction on Jan 02 ’24, Iyengar Vijay K sold 657 shares at 65.00 per share. INCY shares that EVP, GMAPPS owns now total 43,412.
Among the insiders who sold shares, Tray Thomas disposed of 1,067 shares on Dec 13 ’23 at a per-share price of $62.37. This resulted in the Principal Accounting Officer holding 23,436 shares of INCY after the transaction. In another insider transaction, Tray Thomas sold 210 shares at $57.36 per share on Dec 12 ’23. Company shares held by the Principal Accounting Officer now total 24,503.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, INCY has a high of $76.04 and a low of $50.27.
As of this writing, INCY has an earnings estimate of $0.87 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $1.21 per share and a lower estimate of $0.6. The company reported an EPS of $1.1 in the last quarter, which was 7.80% higher than expectations of $1.02.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. INCY’s latest balance sheet shows that the firm has $2.35B in Cash & Short Term Investments as of fiscal 2021. There were $44.82M in debt and $854.31M in liabilities at the time. Its Book Value Per Share was $23.14, while its Total Shareholder’s Equity was $3.77B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for INCY is Buy with a score of 3.95.
